Login to Your Account



Amicus, GSK Extend Their Fabry Disease Collaboration

By Marie Powers
Staff Writer

Thursday, July 19, 2012
Amicus Therapeutics Inc. strengthened ties with partner GlaxoSmithKline plc to develop and commercialize its lead compound, the chaperone migalastat HC1 (Amigal), in Fabry disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription